Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It reports specific share transaction details:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.3450 per share.
- Transaction Volume: 25 shares (Mr. D S Redfern) and 21 shares (Mrs. V A Whyte).
- Transaction Date: April 18, 2017.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of shares by executives.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, management commentary, risk factors, or contingencies. The transactions described were acquisitions of ordinary shares following the re-investment of dividends paid to shareholders on April 13, 2017, on shares held within an Individual Savings Account (ISA).
Key Facts for Investor Verification
- Verify the dividend reinvestment plan terms applicable to the April 13, 2017 dividend payment.
- Confirm the share price of £16.3450 against the London Stock Exchange closing price for April 18, 2017.
- Note that the transactions were executed by the Chief Strategy Officer (Mr. D S Redfern) and the Company Secretary (Mrs. V A Whyte).
- Recognize that this filing does not provide quarterly or annual financial performance data.